Exocrine Pancreatic Insufficiency (EPI) refers to the inability to properly digesting food due to the lack of digestive enzymes made by the pancreas. It is caused due to primary loss of functional parenchyma and/or secondarily impaired exocrine pancreatic function.
Symptoms Related to Exocrine Pancreatic Insufficiency
Various symptoms related to Exocrine Pancreatic Insufficiency include abdominal pain or tenderness, increased gas production, diarrhea, bad-smelling bowel movement, feeling bloated, weight loss, bleeding disorders, bone pain, and intestinal blockage.
Exocrine Pancreatic Insufficiency Epidemiological Segmentation
The Epidemiological Segmentation of Exocrine Pancreatic Insufficiency in 7MM from 2018 to 2030 is segmented into:-
- Prevalence of Causative Indications of Exocrine Pancreatic Insufficiency
- Prevalence of Exocrine Pancreatic Insufficiency
Exocrine Pancreatic Insufficiency Epidemiological Insights Observed in 2018
- The Exocrine Pancreatic Insufficiency prevalence of Causative Indications in Type 2 Diabetes Mellitus in 7MM was found to be 68,271,653.
- Acute Pancreatitis, Chronic Pancreatitis, Cystic Fibrosis, and Unresectable Pancreatic Cancer are assumed to play important roles in Exocrine Pancreatic Insufficiency development.
- In the US, the total number of cases that developed Exocrine Pancreatic Insufficiency from Acute Pancreatitis was 27,995, whereas from Chronic Pancreatitis were 90,111, then from Cystic Fibrosis were 26,583, and lastly from Unresectable Pancreatic Cancer were 24,101.
Exocrine Pancreatic Insufficiency Market
The market size of Exocrine Pancreatic Insufficiency in the 7MM was found to be USD 1,880 million in 2018.
Exocrine Pancreatic Insufficiency Market Drivers
- Research and development strategies
- Demands of advanced therapeutics for the treatment of Exocrine Pancreatic Insufficiency
- Increasing global Exocrine Pancreatic Insufficiency incidences
- Delivery system strategies
Exocrine Pancreatic Insufficiency Market Barriers
- Lack of technological reach and advancements
- Lack of confidence in diagnosis and management
- Treatment failure to stimulate & follow society’s goals and requirements
Exocrine Pancreatic Insufficiency Emerging Drugs
The emerging drugs of the Exocrine Pancreatic Insufficiency market are
- Omeprazole
- MS1819-SD, and others
Exocrine Pancreatic Insufficiency Marketed Drugs
The marketed drugs of the Exocrine Pancreatic Insufficiency market are
- Pertzye
- Creon
- Lipacreon
- Zenpep
- Pancreaze
- Viokace
- RELiZORB
- Ultresa, and others
Exocrine Pancreatic Insufficiency Key Players
The key players working in the Exocrine Pancreatic Insufficiency market are
- Chiesi Farmaceutici
- AzurRx BioPharma
- Digestive Care
- AbbVie
- Nestle
- Janssen Pharmaceuticals
- Aptalis Pharma
- Forest Laboratories
- Alcresta Therapeutics, and several others
Subscribe to our newsletter series to get latest updates on Exocrine Pancreatic Insufficiency treatment landscape